美洛昔康联合奥曲肽增强对肝癌生长的抑制作用

目的美洛昔康和奥曲肽以各自不同的作用机制均能抑制肝癌生长,两者联用其抗肿瘤作用将如何,并不清楚.从不增加不良反应但又能最大限度增加抗肿瘤作用的角度考虑,我们将探讨美洛昔康联合奥曲肽能否协同抑制肝癌细胞生长.方法采用 3H-TdR掺入法探讨美洛昔康和奥曲肽单独或联合应用对人肝癌细胞株HepG2生长的影响,根据中效原理判断两者相互作用的关系;并观察它们对人肝癌裸鼠原位移植瘤生长的影响.结果美洛昔康联合奥曲肽在体外能显著抑制HepG2肝癌细胞的生长,其浓度与 3H-TdR掺入值呈负相关(r=-0.980, P<0.01).美洛昔康联合奥曲肽能显著抑制人肝癌裸鼠原位移植瘤生长,抑瘤率为75.4%,较单药美洛昔康抑瘤率55.1%明显增高(P<0.05 ).各组裸鼠的体内实验中未见明显不良反应.结论体外细胞培养及裸鼠原位移植瘤实验均表明:美洛昔康联合奥曲肽能显著增强抑制肝癌生长的作用,美洛昔康和奥曲肽呈协同作用.

Combination of meloxicam and octreotide enhances the inhibitory effect on growth of human hepatocellular carcinoma

Objective To understand whether meloxicam combined with octreotide could enhance the inhibitory effect on proliferation of hepatic cell carcinoma (HCC). Methods The proliferation of HepG2 HCC cells was measured by 3H-thymidine incorporation into DNA. The synergic effect of meloxicam combined with octreotide on the growth of HepG2 cells was evaluated according to the median-response principle. We also observed the infiuence of combination therapy on the growth of HepG2 xenografts in nude mice. Results The combination of meloxicam and octreotide significantly inhibited 3H-TdR incorporation of HepG2 cells in a dose-dependent manner (r=-0.980, P<0.01). The combination indexes of meloxicam and octreotide in the range of majority responses were less than 1. The inhibition rate (75.4%) of xenografts in nude mice in the combined group was significantly enhanced as compared with that in the meloxicam group (55.1%). No servere side effect was observed in all the treatment groups. Conclusion The combination of meloxicam and octreotide can greatly improve the inhibitory effect on the proliferation of HCC cells in culture as well as the growth of implanted tumors in nude mice.